Dr. Salaheldin Halasa, M.D.

Dr. Salaheldin Halasa, MD, is a physician, researcher, and medical innovator with extensive expertise in immunotherapy, regenerative medicine, nanomedicine, laser therapy, and chronic disease prevention and management. His work focuses on integrating systems biology, immune modulation, metabolic optimization, and advanced therapeutic technologies to develop personalized treatment strategies for cancer, chronic diseases, and age-related conditions.

Dr. Halasa earned his Doctor of Medicine degree from the University of Tripoli Faculty of Medicine in Tripoli, Libya, in 1998. He subsequently passed the United States Medical Licensing Examinations (USMLE), meeting rigorous U.S. medical standards. Early in his career, he conducted research in immunotherapy at Baylor College of Medicine in Texas, contributing to the advancement of immune-based therapeutic approaches.

He is the Founder and Chief Executive Officer of CDPMCS LLC (Chronic Disease Prevention and Management Centers), headquartered in Maryland, where he has developed advanced clinical protocols integrating immunotherapy, stem cell therapy, nanomedicine, photodynamic therapy, and regenerative medicine. His work emphasizes targeting disease at the molecular and systems levels, including modulation of the immune system, tumor microenvironment, oxidative stress, and metabolic dysfunction.

Dr. Halasa is also the Founder of the BeRoyal Institute of Systems Medicine™ and the creator of SysMed.ai™, an artificial intelligence–powered clinical platform designed to integrate genomic, biomarker, and clinical data to optimize personalized treatment.

He is a published author and frequent invited speaker at major international scientific and medical organizations, including the American Academy of Anti-Aging Medicine (A4M), SPIE, the American Society for Laser Medicine and Surgery (ASLMS), the Nitric Oxide Society, ISLA, NAALT, and the Photobiology Society. His work continues to advance precision medicine and nanotechnology-based therapies to improve clinical outcomes worldwide.